Results 181 to 190 of about 3,081 (193)

Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care

Expert Review of Anticancer Therapy
Stefano Molica, David Allsup
openaire   +2 more sources

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3 Open Access

Blood
Andre H Goy, Alejandro Martín García-Sancho, Michael Wang   +2 more
exaly  

Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

Cancer
openaire   +1 more source

Does BTKi improve CAR T-cell therapy in MCL? Free

Blood
M Lia Palomba, Alexander Boardman
exaly  

CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling

International Journal of Biological Macromolecules
Qiuni Chen
exaly  

BTKi bei progredienter Multipler Sklerose besonders geeignet?

DNP – Die Neurologie & Psychiatrie
openaire   +1 more source

The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma

Leukemia
Nathanael Gray, Steven P. Treon, Jinhua Wang   +2 more
exaly  

brain abscess in an immunocompromised patient receiving a second-generation Bruton Tyrosine Kinase inhibitor (BTKi)

Diagnostic Microbiology and Infectious Disease
Spyridon Voulgaris, George A Alexiou, Marios Lampros   +2 more
exaly  

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients

Hematological Oncology
M Dreyling
exaly  

Pirtobrutinib: Nicht-kovalente BTKi-Therapieoption beim MCL

Oncology Research and Treatment
openaire   +1 more source